Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8(+) T Cell Responses via CD169(+) Macrophages and cDC1

Ítems similars

• Optimization of Liposomes for Antigen Targeting to Splenic CD169(+) Macrophages
  per: Nijen Twilhaar, Maarten K., et al.
  Publicat: (2020)
• Selective tumor antigen vaccine delivery to human CD169(+) antigen-presenting cells using ganglioside-liposomes
  per: Affandi, Alsya J., et al.
  Publicat: (2020)
• Activation of CD8(+) T Cell Responses after Melanoma Antigen Targeting to CD169(+) Antigen Presenting Cells in Mice and Humans
  per: van Dinther, Dieke, et al.
  Publicat: (2019)
• Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma
  per: van Dinther, Dieke, et al.
  Publicat: (2018)
• Antigen targeting reveals splenic CD169(+) macrophages as promoters of germinal center B‐cell responses
  per: Veninga, Henrike, et al.
  Publicat: (2015)